AKT1 and neoplasm: For example, PIK3CA gene mutation can activate the PI3K/AKT signaling pathway, increase the mutational load and generation of neoantigens in tumor cells, thereby increasing the response rate of vaccines or cell therapy (Westcott et al., 2023).